Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.05 USD
Change Today +0.04 / 3.96%
Volume 200.0
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/14 - $4.50
52 Week Low
08/27/15 - $0.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company’s pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is headquartered in Buffalo Grove, Illinois.

8 Employees
Last Reported Date: 04/3/15

restorgenex corp (RESX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $562.3K
Chief Financial Officer and Secretary
Total Annual Compensation: $287.7K
Senior Vice President of Clinical Development
Total Annual Compensation: $220.9K
Compensation as of Fiscal Year 2014.

restorgenex corp (RESX) Key Developments

Restorgenex Corporation Reports Earnings Results for the Six Months Ended June 30, 2015

Restorgenex Corporation reported earnings results for the six months ended June 30, 2015. The company has incurred a net loss of $7.5 million, or $0.40 per share, compared to net loss of $5.8 million, or $0.62 per share, for the six months ended June 30, 2014. The increase in the net loss reflects the higher expenses associated with product development of the company's core product, RES-529.

RestorGenex Corporation Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor

RestorGenex Corporation announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines. 3-D cultures grown under physiologically relevant conditions enhance the predictive value for in vivo activity. RestorGenex's lead compound, RES-529, is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that interferes with the molecular components that form TORC1 and TORC2. RES-529 prevents these complexes from generating and potentiating signaling, a characteristic associated with tumor growth and metastasis. In addition, the three RES-529 analogs tested showed activity in a variety of cell lines.

Restorgenex seeking acquisitions

Restorgenex Corporation (OTCPK:RESX) is looking for acquisitions. The company is in the process of acquiring two cosmetic and pharmaceutical companies that develop products that aim to revitalize skin and hair.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $1.05 USD +0.04

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at